6127 (6127) Fair Value & Analysis

Healthcare · Market cap HK$13.9B

6 6127 6127 · HK

PriceHK$19.00

Fair ValueHK$10.29

Upside-45.8%

Quality56/100

Watch 6127 for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range HK$9.36 – HK$12.56

Fair value as of: Jul 2, 2026

From 26 valuation models · updated today

Share price +8.7% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$14.91 – HK$27.72 · fair‑value band HK$9.36 – HK$12.56 · the HK$19.00 price screens above the HK$10.29 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

6127 (6127) currently trades at HK$19.00, while our model-based Fair Value estimate is HK$10.29 — implying the stock looks roughly 45.8% overvalued today. We read business quality at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 6127 generated revenue of HK$1.7B at a net margin of 29.4%. Revenue grew 10.0% year over year. It earns a return on equity of 5.9%. The balance sheet holds a net cash position of HK$910M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$1.7B

Revenue growth (YoY) +10.0%

Net margin 29.4%

Return on equity 5.9%

Free cash flow HK$301M FY2025

P/E ratio 24.1

More key figures

Operating margin -9.7%

EPS (TTM) HK$0.6776

Dividend yield 0.6%

EPS growth (YoY) +540%

Net cash HK$910M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

6127 reported revenue of HK$1.7B in FY2025 versus HK$1.5B in FY2021, a compound +2.2%/yr. Reported net income was HK$298M in FY2025, compounding −14.5%/yr from FY2021.

Revenue +2.2%/yr

FY21 HK$1.5B

FY22 HK$2.3B

FY23 HK$2.4B

FY24 HK$2.0B

FY25 HK$1.7B

Net income −14.5%/yr

FY21 HK$557M

FY22 HK$1.1B

FY23 HK$397M

FY24 HK$74.1M

FY25 HK$298M

Is 6127 fairly valued? → Check now

Similar stocks

6 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Thermo Fisher Scientific Inc TMO	$472.80	$190.31	-60%
Danaher Corporation DHR	$186.64	$85.95	-54%
2359 2359	HK$152.80	HK$120.99	-21%
WuXi AppTec Co WUXAY	$18.59	$25.09	+35%
IDEXX Laboratories, Inc IDXX	$556.94	$255.77	-54%
Lonza Group LZAGY	$63.74	$25.98	-59%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 6127 (6127) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$10.29 versus a price of HK$19.00 — about −46% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 6127?

Our model-based fair value for 6127 is HK$10.29 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$19.00.

What is the quality score of 6127?

6127 has a Quality Score of 56/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 6127 (6127)?

6127 reported trailing-twelve-month revenue of about HK$1.7B (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 6127?

The net profit margin of 6127 is about 29.4%, meaning it keeps roughly 29.4% of revenue as net income. Based on the latest reported figures.

Does 6127 pay a dividend?

6127 currently shows a dividend yield of about 0.62% relative to its recent price (as of Jul 2, 2026).

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.